Ibutilide Fumarate

Atrial Fibrillation
Treatment
3 FDA approvals
20 Active Studies for Ibutilide Fumarate

What is Ibutilide Fumarate

IbutilideThe Generic name of this drug
Treatment SummaryIbutilide is an intravenous medication used to treat abnormal heart rhythms, such as atrial flutter and atrial fibrillation. It works by restoring the normal rhythm of the heart, known as normal sinus rhythm (NSR).
Corvertis the brand name
image of different drug pills on a surface
Ibutilide Fumarate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Corvert
Ibutilide
1995
4

Approved as Treatment by the FDA

Ibutilide, also known as Corvert, is approved by the FDA for 3 uses which include Atrial Fibrillation and Atrial Fibrillation .
Atrial Fibrillation
Helps manage Atrial Fibrillation
Atrial Fibrillation
Helps manage Atrial Fibrillation
Atrial Flutter
Helps manage Atrial Flutter

Effectiveness

How Ibutilide Fumarate Affects PatientsIbutilide affects the electrical activity of the heart, lengthening the time it takes for it to beat and making it harder for abnormal heart rhythms to start. It does this by activating a slow inward current (mostly sodium) at very low amounts, instead of blocking outward potassium currents which is the way most other heart rhythm drugs work.
How Ibutilide Fumarate works in the bodyIbutilide is an intravenous drug that helps treat heart rhythm problems. It works by changing the activity of certain types of potassium and calcium channels in your cells. Specifically, Ibutilide binds to and alters hERG, delayed inward rectifier potassium, and L-type calcium channels.

When to interrupt dosage

The amount of Ibutilide Fumarate is contingent upon the diagnosed condition. The dosage varies, as per the technique of delivery (e.g. Solution or Solution - Intravenous) noted in the table below.
Condition
Dosage
Administration
Atrial Fibrillation
, 0.1 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous

Warnings

There are 20 known major drug interactions with Ibutilide Fumarate.
Common Ibutilide Fumarate Drug Interactions
Drug Name
Risk Level
Description
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Asenapine.
Astemizole
Major
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Astemizole.
Cisapride
Major
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Cisapride.
Ibutilide Fumarate Toxicity & Overdose RiskAnimals who overdose on this drug may experience depression of the central nervous system, rapid breathing, and seizures. The lethal dose for rats is higher than 50mg/kg, which is at least 250 times the maximum recommended human dosage.
image of a doctor in a lab doing drug, clinical research

Ibutilide Fumarate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ibutilide Fumarate?

159 active studies are assessing the potential of Ibutilide Fumarate to ameliorate Atrial Fibrillation.
Condition
Clinical Trials
Trial Phases
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Patient Q&A Section about ibutilide fumarate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ibutilide used for?

"Ibutilide is a medication used to treat atrial flutter and atrial fibrillation by converting them to normal sinus rhythm. It can also be used as a pretreatment for electro cardioversion, though this is not an officially approved use."

Answered by AI

What class of drug is ibutilide?

"Ibutilide is an antiarrhythmic drug that is only available for intravenous use. It is used to terminate atrial arrhythmias."

Answered by AI

What does ibutilide do to the heart?

"Ibutilide belongs to a class of antiarrhythmic drugs called class III agents. Ibutilide enhances the slow inward sodium current, while other class III agents work by blocking cardiac potassium channels. Ibutilide can be used as a one-time intravenous infusion to cardiovert atrial fibrillation or atrial flutter to sinus rhythm chemically."

Answered by AI

How is ibutilide administered?

"The recommended dose of ibutilide for intravenous administration in patients weighing ≥60 kg is 1 mg over a 10-minute period. If the arrhythmia has not terminated, a second 10-minute infusion of equal strength can be given 10 minutes after the end of the initial infusion."

Answered by AI

Clinical Trials for Ibutilide Fumarate

Image of Mission Cardiovascular Research Institute in Fremont, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Fremont, CA
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Phase 2
Recruiting
Mission Cardiovascular Research Institute (+4 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Have you considered Ibutilide Fumarate clinical trials? We made a collection of clinical trials featuring Ibutilide Fumarate, we think they might fit your search criteria.Go to Trials
Image of The Cleveland Clinic in Cleveland, United States.

Metabolic Surgery for Atrial Fibrillation

18 - 80
All Sexes
Cleveland, OH
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Phase 4
Waitlist Available
The Cleveland ClinicAli AminaniEthicon, Inc.
Image of The Ottawa Hospital Civic Campus in Ottawa, Canada.

Cardiac CT Angiography for Atrial Fibrillation and Flutter

18+
All Sexes
Ottawa, Canada
The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management. This will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care. Participants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.
Waitlist Available
Has No Placebo
The Ottawa Hospital Civic CampusBenjamin Chow, MD PhD FRCPC FACC FESC FA
Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Alcohol Abstinence for Atrial Fibrillation

18+
All Sexes
San Francisco, CA
Per the 2021 National Survey on Drug Use and Health administered by the U.S. Department of Health and Human Services, 85% of all American adults consume alcohol. Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million individuals in U.S., comprising 4.5% of the adult population. Although alcohol abstinence clearly reduces AF in heavy drinkers, observational data comparing the health effects of limited consumption versus abstention are conflicting. The Mediterranean diet is one of the few that has demonstrated clear cardiovascular benefits in a randomized study-this diet allows for the consumption of red wine (or high polyphenol/ low alcohol alcohol), generally not more than one drink in 24 hours, with meals, avoiding spirits and binge drinking. The effect of the "Mediterranean drinking pattern" on AF risk compared to alcohol abstinence remains unknown. This single center, randomized, controlled trial aims to compare the effects of a digital health intervention to encourage durable alcohol abstinence versus allowing guideline-adherent moderate alcohol consumption on AF severity. The knowledge gained from this study may be used to determine optimal thresholds for alcohol use among AF patients.
Recruiting
Has No Placebo
UCSF Medical Center at ParnassusGregory M Marcus, MD, MAS
Have you considered Ibutilide Fumarate clinical trials? We made a collection of clinical trials featuring Ibutilide Fumarate, we think they might fit your search criteria.Go to Trials
Image of VA Palo Alto Health Care System, Palo Alto, CA in Palo Alto, United States.

Zio XT® Patch for Atrial Fibrillation

65+
All Sexes
Palo Alto, CA
* The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure. * Atrial fibrillation is a common heart condition in which one of the heart chambers doesn't follow a normal rhythm. Blood clots can form as a result, and they can travel to the brain and cause strokes, or to other organs. * Almost everyone with atrial fibrillation is treated with drugs called anticoagulants ("blood thinners") to reduce the risk of stroke. These drugs also increase the risk of bleeding. * Testing for atrial fibrillation is usually done for patients who have symptoms of an irregular or unusually fast or slow heartbeat, often called "palpitations" or a sensation of the heart pounding or stopping for a short period of time. * What is not known is whether screening people who do not have symptoms of atrial fibrillation, but who are at above-average risk of getting atrial fibrillation, will reduce death, hospitalization for stroke, blood clots, heart failure more than it increases hospitalization for severe bleeding. * People who participate in the trial who are selected by chance to receive screening will wear a small heart-rate monitor (Zio Patch) on their skin for 14 days and then return it to the manufacturer. Their doctors will be notified about the results and will make decisions about any treatment to recommend. * The screening trial is expected to enroll about 24,000 VA patients nationwide and to last 7 years, but each person's active participation in the trial is completed after sending in the Zio Patch. After that, the study team will just collect information from the participant's electronic medical records.
Waitlist Available
Has No Placebo
VA Palo Alto Health Care System, Palo Alto, CAPaul A. Heidenreich, MD MS
Image of VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA in Boston, United States.

Apixaban vs Rivaroxaban for Atrial Fibrillation

65+
All Sexes
Boston, MA
* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib"). * We will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.
Phase 4
Waitlist Available
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MACara N Pellegrini
Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Exercise for Atrial Fibrillation

18+
All Sexes
New York, NY
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, paroxysmal AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.
Recruiting
Has No Placebo
Icahn School of Medicine at Mount SinaiJanice Y Chyou, MD
Have you considered Ibutilide Fumarate clinical trials? We made a collection of clinical trials featuring Ibutilide Fumarate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security